- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07941297
Virtual Reality-Based Cognitive-Motor Rehabilitation in Traumatic Brain Injury
Novel Virtual Reality-Based Cognitive-Motor Rehabilitation for Individuals With Traumatic Brain Injury
This study aims to evaluate the feasibility, safety, and efficacy of a novel virtual reality (VR)-based cognitive-motor rehabilitation program for individuals with traumatic brain injury (TBI). The intervention uses the Virtual Reality Color Trails Test (VR-CTT), which combines cognitive tasks with upper-limb movements in an immersive virtual environment.
The study consists of two stages. The first stage is a feasibility pilot involving 15 participants who will complete three VR training sessions over one week. The second stage is a randomized controlled trial involving 80 participants allocated to either VR-CTT training combined with standard rehabilitation or a control group receiving standard rehabilitation with additional therapy time. The intervention will consist of nine sessions over three weeks.
The study will assess feasibility, safety, executive functions, upper-limb motor performance, balance, and functional outcomes.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Traumatic brain injury (TBI) frequently results in cognitive and motor impairments that affect everyday functioning. Conventional rehabilitation often addresses these domains separately, although many daily activities require their simultaneous integration. This study evaluates a rehabilitation approach based on the Virtual Reality Color Trails Test (VR-CTT), an immersive system developed at Sheba Medical Center that combines cognitive challenges with coordinated head and upper-limb movements.
The study consists of two sequential stages.
**Stage 1: Feasibility Pilot**
Fifteen participants with TBI will receive three VR-CTT training sessions over one week in addition to standard rehabilitation. Training will progress from seated tasks to more challenging standing activities according to individual abilities. This stage will assess feasibility, safety, usability, and participant satisfaction to inform implementation of the subsequent trial.
**Stage 2: Randomized Controlled Trial**
Eighty participants with TBI will be randomly assigned in a 1:1 ratio to two parallel groups. The intervention group will receive standard rehabilitation supplemented by nine VR-CTT training sessions over three weeks. Training difficulty will increase progressively through changes in cognitive demands, the number of targets, body position, and unilateral or bilateral hand use.
The control group will receive standard rehabilitation supplemented by additional cognitive or motor therapy to match the total treatment time of the intervention group.
Outcome assessments will be conducted before and after the intervention period and will include measures of executive functioning, upper-limb motor performance, balance, everyday functioning, and cognitive-motor interaction. Outcome assessors will remain blinded to group allocation during the randomized stage.
The study aims to determine whether integrated VR-based cognitive-motor training is feasible and safe and whether it improves cognitive and motor outcomes compared with conventional rehabilitation.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Amihai Gottlieb, Ph.D
- Numéro de téléphone: +972543323180
- E-mail: amihai.gottlieb@gmail.com
Lieux d'étude
-
-
-
Ramat Gan, Israël
- Sheba Medical Center
-
Contact:
- Amihai Gottlieb, Ph.D
- Numéro de téléphone: +972543323180
- E-mail: amihai.gottlieb@gmail.com
-
Sous-enquêteur:
- Meir Plotnik, Prof.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
**Inclusion Criteria:**
- Men and women aged 18-50 years.
- Admitted for inpatient rehabilitation following traumatic brain injury (TBI).
- Glasgow Coma Scale (GCS) score of 9-15 at admission.
- Brain CT positive for acute intracranial trauma (including complicated mild or moderate TBI).
- Presence of cognitive and motor symptoms as determined by clinical evaluation.
- Sufficient decision-making capacity to provide informed consent.
**Exclusion Criteria:**
- Inability to meaningfully comprehend the study procedures (e.g., severe aphasia or cognitive impairment), as determined through a structured capacity assessment.
- Severe physical limitations that prevent the use of VR equipment (e.g., severe upper-limb fractures preventing controller use).
- History of epilepsy or seizures triggered by flashing lights.
- Severe visual or vestibular impairments that would make VR exposure unsafe (e.g., severe vertigo).
- Active psychiatric conditions (e.g., acute psychosis) likely to interfere with adherence to study procedures.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Stage 1: VR-CTT Feasibility Pilot
Fifteen participants with traumatic brain injury will receive standard rehabilitation supplemented by three VR-CTT training sessions over one week. Sessions will last approximately 45 minutes and progress from seated activities to standing activities according to participants' abilities. This stage will evaluate feasibility, safety, and usability. |
An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2. |
|
Expérimental: Stage 2: VR-CTT Training
Forty participants will receive standard inpatient rehabilitation supplemented by nine VR-CTT training sessions over three weeks (three sessions per week, approximately 45 minutes each). Training will progressively increase cognitive and motor demands through changes in target number, task complexity, posture, and hand use. |
An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2. |
|
Comparateur actif: Stage 2: Active Control
Forty participants will receive standard inpatient rehabilitation supplemented by approximately three hours per week of additional cognitive or motor therapy with a therapist or volunteer, without VR-CTT training. The additional therapy is intended to match the total treatment time of the intervention group. |
Additional cognitive or motor rehabilitation exercises administered by a therapist or volunteer, supplementing standard inpatient rehabilitation. Participants receive approximately three hours of additional therapy per week over three weeks to match the total treatment time provided to the VR-CTT intervention group. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Executive Function Composite Score
Délai: Baseline (Week 0) and post-intervention (Week 4).
|
Change in executive functioning assessed using a composite score derived from the Stroop Test, Rule Shift Cards Test (BADS), and Montreal Cognitive Assessment (MoCA). Standardized scores will be used to evaluate changes in executive control, including inhibition, cognitive shifting, and mental flexibility. |
Baseline (Week 0) and post-intervention (Week 4).
|
|
Change in Upper Limb Motor Function (ARAT)
Délai: Baseline (Week 0) and post-intervention (Week 4).
|
Change in upper limb motor function assessed using the Action Research Arm Test (ARAT), which evaluates upper extremity motor performance and coordination. Higher scores indicate better motor function. |
Baseline (Week 0) and post-intervention (Week 4).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Functional Status (FSE)
Délai: Baseline (Week 0) and post-intervention (Week 4).
|
Change in everyday functional outcomes assessed using the Functional Status Examination (FSE), which evaluates functional limitations following traumatic brain injury. |
Baseline (Week 0) and post-intervention (Week 4).
|
|
Change in Balance (Berg Balance Scale)
Délai: Baseline (Week 0) and post-intervention (Week 4).
|
Change in static and dynamic balance assessed using the Berg Balance Scale (BBS). Higher scores indicate better balance performance. |
Baseline (Week 0) and post-intervention (Week 4).
|
|
Change in Cognitive-Motor Performance (VR Supermarket Task)
Délai: Baseline (Week 0) and post-intervention (Week 4).
|
Change in performance on a virtual reality-based supermarket task assessing cognitive-motor integration, including divided attention and sustained attention during simulated everyday activities. |
Baseline (Week 0) and post-intervention (Week 4).
|
|
Change in Dual-Task Performance (Box and Block Test)
Délai: Baseline (Week 0) and post-intervention (Week 4).
|
Change in dual-task performance assessed using the Dual-Task Box and Block Test (BBT-DT), in which participants transfer blocks while simultaneously performing mental arithmetic. |
Baseline (Week 0) and post-intervention (Week 4).
|
|
Feasibility of VR-CTT Training
Délai: During the one-week pilot intervention (Stage 1).
|
Feasibility assessed by adherence to the planned VR-CTT training protocol, including the proportion of scheduled training sessions completed by participants. |
During the one-week pilot intervention (Stage 1).
|
|
Simulator Sickness Symptoms
Délai: After each VR training session during the one-week pilot (Stage 1).
|
Simulator sickness symptoms, including nausea, dizziness, headache, and eyestrain, assessed after VR training sessions using the Simulator Sickness Questionnaire (SSQ). |
After each VR training session during the one-week pilot (Stage 1).
|
|
VR-CTT Usability and Participant Satisfaction
Délai: At completion of the one-week pilot intervention (Stage 1).
|
Usability and participant satisfaction with the VR-CTT system assessed using post-training feedback questionnaires addressing comfort, ease of use, and overall experience. |
At completion of the one-week pilot intervention (Stage 1).
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SHEBA-26-3045-GZ-CTIL
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .